Search clinical trials for: LEO 152020 placebo tablet

Total 2479 results

LEO Pharma

Completed

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland, Spain, Australia, Japan
JW Pharmaceutical
LEO Pharma

Completed

A Trial to Evaluate the Effect of Food on LEO 152020

Healthy

United States, United Kingdom
JW Pharmaceutical
LEO Pharma

Completed

Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

Cholinergic Urticaria

Germany
Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Atridia Pty Ltd.

Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Inflammatory Bowel Disease

Australia
Paratek Pharmaceuticals Inc

Active, not recruiting

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Mycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary Infection

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
LEO Pharma

Completed

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
Rigshospitalet, Denmark

Completed

The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.

Hyponatremia | Metabolic Bone Disease

Denmark
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
LEO Pharma

Active, not recruiting

Investigating the Safety of LEO 158968 in Healthy Volunteers

Healthy Volunteers

Netherlands
LEO Pharma

Completed

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States, Canada
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

Atopic Dermatitis

United Kingdom
Hansoh BioMedical R&D Company

Not yet recruiting

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Vasomotor Symptoms

China
LEO Pharma

Recruiting

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, France, Germany, Japan, Poland, United Kingdom, Czechia, Spain, Romania, Hungary
LEO Pharma

Withdrawn

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

Healthy

United Kingdom
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
JW Pharmaceutical
LEO Pharma

Completed

A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People

Healthy Volunteers | Cardiac Repolarisation

United Kingdom
LEO Pharma
ICON plc

Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Healthy Volunteers

Netherlands
LEO Pharma

Completed

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Unknown

Expanding Phase III Study of Tyroserleutide for Injection

Hepatocellular Carcinoma
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Damanhour University

Completed

Ivabradine in Patients With Congestive Heart Failure

Congestive Heart Failure

Egypt
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy (ESPRIT)

Ischemic Stroke, Acute

China
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
Harmony Biosciences, LLC

Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
Xgene Pharmaceutical Group

Recruiting

XG005 for Pain Control in Subjects Undergoing Bunionectomy

Acute Pain

United States
Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical(Australia) Pty Ltd.

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers

Healthy

Australia
University of California, Los Angeles

Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Sequel Pharmaceuticals, Inc

Terminated

Phase 2 Study of Oral K201 for Prevention of AF Recurrence (ARCTIC-AF)

Atrial Fibrillation
China Resources Sanjiu Medical & Pharmaceutical...

Not yet recruiting

Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).

Ankylosing Spondylitis

China
Haisco Pharmaceutical Group Co., Ltd.

Completed

Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers

Healthy Volunteers

China
Stallergenes Greer

Completed

Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

Seasonal Allergic Rhinitis

Austria
Stallergenes Greer

Completed

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Allergy

Germany
Vaxart

Completed

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (VXA-NVV-103)

Norovirus Infection

United States
Vaxart

Completed

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Norovirus Gastroenteritis

United States
Stallergenes Greer

Completed

Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma

Asthma | House Dust Mite Allergy

France, Germany, Poland
LEO Pharma

Completed

LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Hansoh BioMedical R&D Company

Recruiting

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

Focal Segmental Glomerulosclerosis | IgA Nephropathy

China

3

Subscribe